Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia

作者：Chau Edith J; Mostaid Md Shaki; Cropley Vanessa; McGorry Patrick; Pantelis Christos; Bousman Chad A; Everall Ian P^*

来源：Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85: 1-6.

DOI：10.1016/j.pnpbp.2018.03.010

• SELENBP1
• Gene expression
• Protein expression
• Recent-onset schizophrenia
• Treatment-resistant schizophrenia
• Biomarker analysis

Upregulation of selenium binding protein 1 (SELENBP1) mRNA expression has been reported in schizophrenia, primarily in the dorsolateral prefrontal cortex. However, peripheral blood studies are limited and results are inconsistent. In this study, we examined SELENBP1 mRNA expression in whole blood and protein expression in plasma from patients with recent-onset schizophrenia (n= 30), treatment-resistant schizophrenia (n = 71) and healthy controls (n = 57). We also examined the effects of SELENBP1 genetic variation on gene and protein expression. We found lower SELENBP1 plasma protein levels in patients with recent-onset schizophrenia (p = 0.042) but not in treatment-resistant schizophrenia (p = 0.81). Measurement of peripheral mRNA levels showed no difference between treatment-resistant schizophrenia and healthy controls (p = 0.234) but clozapine plasma levels (p = 0.036) and duration of illness (p = 0.028) were positively correlated with mRNA levels. Genetic variation was not associated with mRNA or protein expression. Our data represent the first peripheral proteomic study of SELENBP1 in schizophrenia and suggest that plasma SELENBP1 protein is downregulated in patients with recent-onset schizophrenia.

• 出版日期2018-7-13